The bill HB2489 amends Arizona's controlled substances laws to declare that any FDA-approved compound containing 3,4-methylenedioxymethamphetamine (MDMA) that is rescheduled by the U.S. Drug Enforcement Administration (DEA) to a schedule other than schedule I is considered a controlled substance and may be prescribed in Arizona. This change is contingent upon federal approval of an MDMA product and aims to facilitate rapid access to this treatment option for patients, particularly for conditions like PTSD.

Additionally, the bill requires the Director of the Arizona State Board of Pharmacy to notify the Legislative Council by February 1, 2026, regarding the status of the MDMA product approval. The legislation is titled the "PTSD Treatment Act of 2023" and includes provisions for conforming changes and a legislative findings clause. The effective date of the bill is set for January 1, 2026, subject to the fulfillment of the specified conditions.

Statutes affected:
Introduced Version: 28-1326
House Engrossed Version: 36-2511, 36-2517.01, 36-2512, 36-2513, 36-2514, 36-2515, 36-2516, 36-2517
Chaptered Version: 36-2511, 36-2517.01, 36-2512, 36-2513, 36-2514, 36-2515, 36-2516, 36-2517